{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DE+CT&page=4",
    "query": {
      "intervention": "DE CT",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 96,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DE+CT&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DE+CT&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T03:14:36.640Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01236560",
      "title": "Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Brain Stem Glioma",
        "Cerebral Astrocytoma",
        "Childhood Cerebellar Anaplastic Astrocytoma",
        "Childhood Cerebral Anaplastic Astrocytoma",
        "Childhood Spinal Cord Neoplasm"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "3 Years to 21 Years"
      },
      "enrollment_count": 101,
      "start_date": "2011-01-26",
      "completion_date": "2023-12-31",
      "has_results": true,
      "last_update_posted_date": "2024-02-20",
      "last_synced_at": "2026-11-05T03:14:36.640Z",
      "location_count": 124,
      "location_summary": "Birmingham, Alabama • Downey, California • Loma Linda, California + 98 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01236560"
    },
    {
      "nct_id": "NCT01530997",
      "title": "De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Squamous Cell",
        "Head and Neck Neoplasms",
        "Oropharyngeal Neoplasms"
      ],
      "interventions": [
        {
          "name": "Intensity Modulated Radiotherapy (IMRT)",
          "type": "RADIATION"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Limited surgical evaluation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2012-02-07",
      "completion_date": "2019-11",
      "has_results": true,
      "last_update_posted_date": "2024-11-13",
      "last_synced_at": "2026-11-05T03:14:36.640Z",
      "location_count": 5,
      "location_summary": "Colorado Springs, Colorado • Gainesville, Florida • Chapel Hill, North Carolina + 1 more",
      "locations": [
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01530997"
    },
    {
      "nct_id": "NCT02779283",
      "title": "Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Idarubicin",
          "type": "DRUG"
        },
        {
          "name": "Idelalisib",
          "type": "DRUG"
        },
        {
          "name": "In Vitro Kinase Inhibitor Assay",
          "type": "DEVICE"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone Sodium Succinate",
          "type": "DRUG"
        },
        {
          "name": "Ponatinib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ruxolitinib Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib Tosylate",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib Malate",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "BIOLOGICAL"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 7,
      "start_date": "2016-01-13",
      "completion_date": "2018-09-20",
      "has_results": false,
      "last_update_posted_date": "2020-05-26",
      "last_synced_at": "2026-11-05T03:14:36.640Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02779283"
    },
    {
      "nct_id": "NCT06644183",
      "title": "Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Relapsed Leukemia",
        "Chronic Lymphocytic Leukemia",
        "Relapsed Cancer",
        "Refractory Leukemia"
      ],
      "interventions": [
        {
          "name": "Roginolisib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jennifer R. Brown, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2025-03-19",
      "completion_date": "2032-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-11",
      "last_synced_at": "2026-11-05T03:14:36.640Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06644183"
    },
    {
      "nct_id": "NCT04214249",
      "title": "BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome",
        "Acute Myeloid Leukemia Post Cytotoxic Therapy",
        "Secondary Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Hematopoietic Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Idarubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Punch Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 49,
      "start_date": "2021-02-17",
      "completion_date": "2027-01-30",
      "has_results": true,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-11-05T03:14:36.640Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Orange, California • New Haven, Connecticut + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04214249"
    },
    {
      "nct_id": "NCT05675410",
      "title": "A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bleomycin Sulfate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Brentuximab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Etoposide Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Fludeoxyglucose F-18",
          "type": "OTHER"
        },
        {
          "name": "Involved-site Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Prednisolone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Procarbazine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Vinblastine Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "5 Years to 60 Years"
      },
      "enrollment_count": 1875,
      "start_date": "2023-05-11",
      "completion_date": "2031-04-28",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-05T03:14:36.640Z",
      "location_count": 404,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 298 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05675410"
    },
    {
      "nct_id": "NCT01193842",
      "title": "Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "AIDS-Related Plasmablastic Lymphoma",
        "AIDS-Related Primary Effusion Lymphoma",
        "Ann Arbor Stage I Diffuse Large B-Cell Lymphoma",
        "Ann Arbor Stage I Grade 3 Follicular Lymphoma",
        "Ann Arbor Stage II Diffuse Large B-Cell Lymphoma",
        "Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma",
        "Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma",
        "Ann Arbor Stage III Diffuse Large B-Cell Lymphoma",
        "Ann Arbor Stage III Grade 3 Follicular Lymphoma",
        "Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma",
        "Ann Arbor Stage IV Grade 3 Follicular Lymphoma",
        "HIV Infection",
        "Plasmablastic Lymphoma",
        "Primary Effusion Lymphoma",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 107,
      "start_date": "2010-10-06",
      "completion_date": "2022-05-19",
      "has_results": true,
      "last_update_posted_date": "2023-11-21",
      "last_synced_at": "2026-11-05T03:14:36.640Z",
      "location_count": 35,
      "location_summary": "Montgomery, Alabama • La Jolla, California • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01193842"
    },
    {
      "nct_id": "NCT02541565",
      "title": "Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Composite Lymphoma",
        "Grade 3b Follicular Lymphoma",
        "Stage I Diffuse Large B-Cell Lymphoma",
        "Stage I Follicular Lymphoma",
        "Stage II Diffuse Large B-Cell Lymphoma",
        "Stage II Follicular Lymphoma",
        "Stage III Diffuse Large B-Cell Lymphoma",
        "Stage III Follicular Lymphoma",
        "Stage IV Diffuse Large B-Cell Lymphoma",
        "Stage IV Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2015-11-24",
      "completion_date": "2018-12-18",
      "has_results": true,
      "last_update_posted_date": "2020-10-14",
      "last_synced_at": "2026-11-05T03:14:36.640Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02541565"
    },
    {
      "nct_id": "NCT04166318",
      "title": "Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anal Basaloid Carcinoma",
        "Anal Canal Cloacogenic Carcinoma",
        "Anal Canal Squamous Cell Carcinoma",
        "Anal Margin Squamous Cell Carcinoma",
        "Stage I Anal Cancer AJCC v8",
        "Stage IIA Anal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludeoxyglucose F-18",
          "type": "OTHER"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Mitomycin",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 252,
      "start_date": "2020-01-02",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-05T03:14:36.640Z",
      "location_count": 659,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 438 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04166318"
    },
    {
      "nct_id": "NCT07220187",
      "title": "Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Richter Syndrome",
        "Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma",
        "Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Pirtobrutinib",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rituximab and Hyaluronidase Human",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2026-08-04",
      "completion_date": "2036-10",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-05T03:14:36.640Z",
      "location_count": 62,
      "location_summary": "Irvine, California • Laguna Hills, California • Orange, California + 48 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Bloomington",
          "state": "Illinois"
        },
        {
          "city": "Canton",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07220187"
    }
  ]
}